+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether N-acetylcysteine NAC can help prevent post-tuberculosis lung disease PTLD in patients who have severe lung problems caused by pulmonary tuberculosis. The study also monitors the safety of NAC. It aims to find out if NAC improves lung function measured by FEV1% over 12 months in patients with pulmonary tuberculosis and risk factors for PTLD, and what medical issues or side effects occur during treatment. The trial compares NAC plus standard TB treatment to standard TB treatment alone. Participants will be randomly assigned to receive either NAC at a dose of 1800 mg twice daily along with standard TB treatment for the first 6 months, or standard TB treatment alone for 6 months. After the treatment period, participants will be followed for an additional 6 months. Standard TB treatment consists of fixed dose combination tablets. The trial is open-label and has parallel groups. During the 12-month study, participants will attend scheduled clinic visits for respiratory assessments, blood tests, and symptom monitoring. They will also complete quality-of-life questionnaires and provide sputum and blood samples at various times. Researchers will measure lung function, respiratory symptoms, quality of life, and laboratory markers including sputum culture and blood glutathione. Safety will be monitored through recording adverse events and liver function tests.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.

Age: 1Day - 49YearsAll GendersPhase 3
219 locations